이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Porton Pharma Solutions 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Nianfeng Ju

최고 경영자

CN¥1.9m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	10.8%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	2.3yrs

최근 관리 업데이트

Recent updates

CEO

Nianfeng Ju (52 yo)

no data

테뉴어

CN¥1,931,300

보상

Mr. Nianfeng Ju serves as General Manager of Porton Imp & Exp Ltd. Nianfeng Ju served as the General Manager of Porton Co., Ltd. He serves as a General Manager of Porton Pharma Solutions Ltd.Mr. Ju serves...

리더십 팀

이름	위치	테뉴어	보상	소유권
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.79% CN¥ 696.1m
Hui Chen	Deputy GM & CFO	2.3yrs	CN¥1.59m	데이터 없음
Yinchun Bai	Senior Deputy GM & COO	2.3yrs	CN¥1.65m	0.029% CN¥ 1.8m
Pi Wei	Deputy General Manager & Secretary	2.3yrs	CN¥714.90k	0.0082% CN¥ 531.8k
Zhongneng Wang	Deputy General Manager	2.3yrs	CN¥1.39m	0.026% CN¥ 1.7m
Fengping Wang	Deputy General Manager	2.3yrs	CN¥2.09m	0.020% CN¥ 1.3m
Qi Chen	Deputy General Manager	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: 300363 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.79% CN¥ 696.1m
Weiqiang Yang	Non Independent Director	2.9yrs	CN¥180.00k	데이터 없음
Guohua Cao	Independent Director	3.8yrs	CN¥180.00k	데이터 없음
Hui Zeng	Employee Representative Supervisor	no data	CN¥212.80k	데이터 없음
Lin Yuan	Independent Director	2.3yrs	CN¥180.00k	데이터 없음
Jinwei Pang	Independent Director	2.3yrs	CN¥180.00k	데이터 없음
Yongqing Tan	Non-Employee Supervisory Board Chairman	no data	데이터 없음	데이터 없음
Ying Xue	Non-Independent Director	3.8yrs	CN¥180.00k	0.0027% CN¥ 173.6k
Jun Zhu	Director	1.4yrs	데이터 없음	데이터 없음
Lina Hu	Non-Independent Director	2.3yrs	CN¥180.00k	데이터 없음
Guojun Cao	Non-Independent Director	2.3yrs	CN¥180.00k	데이터 없음
Yuchen Wu	Non-Employee Supervisor	2.3yrs	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: 300363 의 이사회는 경험(평균 재직 기간 2.2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Porton Pharma Solutions 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new directors

High number of new and inexperienced directors

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Recent updates

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 16%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New major risk - Revenue and earnings growth

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Full year 2022 earnings released: EPS: CN¥3.70 (vs CN¥0.97 in FY 2021)

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS: CN¥0.70 (vs CN¥0.16 in 1Q 2021)

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Revenue beats expectations

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13

Investor sentiment improved over the past week

New 90-day high: CN¥39.66

Third quarter earnings released

Porton Pharma Solutions Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Market bids up stock over the past week

New 90-day high: CN¥38.90

Porton Pharma Solutions Ltd. Announces Board Changes

Earnings released

Porton Pharma Solutions Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령